Forte Biosciences (FBRX) Accounts Payables (2016 - 2026)

Forte Biosciences (FBRX) has reported Accounts Payables for 11 consecutive years, with $13.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accounts Payables rose 160.48% year-over-year to $13.1 million; the TTM figure through Mar 2026 stood at $13.1 million (up 160.48% YoY), while the FY2025 annual figure was $10.0 million, up 104.73% from the prior year.
• Accounts Payables advanced to $13.1 million in Q1 2026 per FBRX's latest filing, from $10.0 million in the prior quarter.
• Across five years, Accounts Payables topped out at $13.1 million in Q1 2026 and bottomed at $576000.0 in Q1 2022.
• Historically, Accounts Payables has averaged $4.2 million across 5 years, with a median of $4.9 million in 2024.
• Annual changes were most pronounced in 2022 — Accounts Payables slumped 48.88% — and 2023, when it jumped 349.54%.
• Forte Biosciences' Accounts Payables stood at $1.2 million in 2022, then rose by 23.5% to $1.4 million in 2023, then surged by 242.63% to $4.9 million in 2024, then surged by 104.73% to $10.0 million in 2025, then jumped by 30.98% to $13.1 million in 2026.
• Business Quant data shows FBRX's Accounts Payables at $13.1 million in Q1 2026, $10.0 million in Q4 2025, and $5.5 million in Q3 2025.